Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019
September 23 2019 - 7:00AM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
today announced that it will present several posters highlighting
clinical data from three of its ongoing programs for oral
paclitaxel and encequidar (“Oral Paclitaxel”; f.k.a Oraxol or oral
paclitaxel and HM30181) at the European Society for Medical
Oncology (ESMO) Congress 2019 to be held September 27 – October 1,
2019 in Barcelona, Spain. The posters demonstrate the results from
clinical studies of Oral Paclitaxel for patients with a number of
advanced solid tumor types as well as in combination with
ramucirumab, an anti-VEGFR2 antibody therapy.
Please see the presentation details below. The abstracts can be
found within the conference calendar here.
Poster: |
477P |
Title: |
An international randomized cross-over bio-equivalence study of
oral paclitaxel + HM30181 compared with weekly intravenous (IV)
paclitaxel in patients with advanced solid tumors |
Session: |
Poster Display session |
Date: |
September 28, 2019 |
Time: |
12:00 - 13:00 CEST |
Location: |
Poster Area (Hall 4) |
Speaker: |
Edmond Ang (New Zealand) |
|
|
Poster: |
1733TiP |
Title: |
A pilot study of oral paclitaxel (ORAXOL) in subjects with
cutaneous angiosarcomas (KX-ORAX-010) |
Session: |
Poster Display session |
Date: |
September 28, 2019 |
Time: |
12:00 - 13:00 CEST |
Location: |
Poster Area (Hall 4) |
Speaker: |
Herbert H. Loong (Shatin, Hong Kong PRC) |
|
|
Poster: |
800P |
Title: |
A Phase 1b Study of Oraxol in combination with ramucirumab in
patients with gastric or esophageal cancers who failed previous
chemotherapy |
Date: |
September 29, 2019 |
Time: |
12:00 - 13:00 CEST |
Session: |
Poster Display session |
Location: |
Poster Area (Hall 4) |
Speaker: |
Ming Huang Chen (Taipei City, Taiwan) |
The Orascovery platform was initially developed by Hanmi
Pharmaceuticals and licensed exclusively
to Athenex for all major worldwide territories
except Korea, which is retained by Hanmi.
About Athenex, Inc. Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development and commercialization of next generation
drugs for the treatment of cancer. Athenex is organized
around three platforms, including an Oncology Innovation Platform,
a Commercial Platform and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on non-absorbed
P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan; multiple locations
in Chongqing, China; and Manchester, UK. For more
information, please visit www.athenex.com.
Forward-Looking Statements Except for
historical information, all of the statements, expectations, and
assumptions contained in this press release are forward-looking
statements. These forward-looking statements are typically
identified by terms such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “evaluate,” “expect,” “foresee,” “guidance,”
“intend,” “investigate,” “likely,” “may,” “plan,” “potential,”
“predict,” “preliminary,” “prepare,” “potential,” “probable,”
“project,” “promising,” “seek,” “should,” “will,” “would,” and
similar expressions. Actual results might differ materially
from those explicit or implicit in the forward-looking statements.
Important factors that could cause actual results to differ
materially include: the development stage of our primary clinical
candidates and related risks involved in drug development, clinical
trials, regulation, manufacturing and commercialization; our
reliance on third parties for success in certain areas of
Athenex’s business; our history of operating losses and need to
raise additional capital to continue as a going concern;
competition; intellectual property risks; risks relating to doing
business in China; the uncertainty of when, if at all, we will
be able to resume producing API in our Chongqing plant;
and the other risk factors set forth from time to time in
our SEC filings, copies of which are available for free
in the Investor Relations section of our website
at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or
upon request from our Investor Relations Department. All
information provided in this release is as of the date hereof and
we assume no obligation and do not intend to update these
forward-looking statements, except as required by law.
CONTACTS Investor Relations: Tim McCarthy
Managing Director, LifeSci Advisors, LLC Tel: +1
716-427-2952 Direct: +1 212-915-2564
Athenex, Inc.: Randoll Sze Chief Financial Officer
Email: randollsze@athenex.com
Jacqueline Li Corporate Development and Investor Relations
Email: jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Sep 2023 to Sep 2024